lenacapavir

The development of lenacapavir, a twice-yearly injectable drug, has been named the 2024 Breakthrough of the Year by Science journal for its potential to significantly reduce new HIV infections and reshape global HIV prevention efforts. Clinical trials, PURPOSE 1 and PURPOSE 2, showed lenacapavir’s remarkable efficacy in preventing HIV, with nearly 100% effectiveness among cisgender […]